A Study to Assess the Antibody Response of Healthy Chinese Children Who Have Been Vaccinated Previously With 4-doses of Prevenar (a Pneumococcal Vaccine) as Babies and Toddlers

A Phase 4, Open-label Study to Evaluate Persistence of the Antibody Response Elicited by Prevenar in Healthy Children in China Who Have Been Previously Immunized With a 4-dose Series of a Pneumococcal Conjugate Vaccine During Infancy in Study 0887x-101518

In 2005, Wyeth conducted study 0887X-101518 (NCT00488826) in which Chinese infants received either Prevenar alone (Group 1), Prevenar given with a Diphtheria, Tetanus and acellular Pertussis (DTaP) vaccine (Group 2) or DTaP alone (Group 3). This follow up study (at least 3 years after the last vaccination) will assess the antibody concentrations in children who previously completed Wyeth study 0887X-101518.

Inclusion Criteria:

• Male or female subjects who participated in and completed Wyeth study 0887X 101518.
• Healthy subject as determined by medical history, physical examination, and judgment of the investigator.

Exclusion Criteria:

• Vaccination with any licensed or investigational pneumococcal vaccine since completion of Wyeth study 0887X 101518.
• History of culture proven invasive disease caused by S pneumoniae since the completion of Wyeth study 0887X 101518.
• Known or suspected immune deficiency or suppression since participation in Wyeth study 0887X 101518.